We have evaluated anakinra drug retention rate and predictive factors of drug survival in a cohort of patients with systemic juvenile idiopathic arthritis (sJIA) and adult onset Still’s disease (AOSD). Our findings show an overall excellent drug retention rate of anakinra on the long run for both sJIA and AOSD that may be further optimized by closely monitoring patient’s safety issues and employing this interleukin-1 inhibitor as a first-line biologic drug as early as possible. Moreover, the use of anakinra allowed a significant other drug-sparing effect while showing a good safety profile.
|Numero di pagine||2|
|Rivista||PEDIATRIC RHEUMATOLOGY ONLINE JOURNAL|
|Volume||10th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID)|
|Stato di pubblicazione||Pubblicato - 2019|